Loading
NASDAQHealthcareBiotechnology
Latest quote
$15.1014
−$1.3286 · -8.09%
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Regular session
$15.1014
−$1.3286 · -8.09%
Regular session · ET · Market data may be delayed.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Day range
Current $15.1014
52-week range
Current $15.1014
Regular session · ET · Market data may be delayed.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Day range
Current $15.1014
52-week range
Current $15.1014
| Metric (USD) | FY2025 |
|---|---|
| Research and development | 109.11M USD |
| Selling, general, and administrative | 49.23M USD |
| Operating expenses | 158.34M USD |
| Interest income | 11.05M USD |
| Depreciation and amortization | 310K USD |
| Operating income | −158.34M USD |
| Net income | −148.96M USD |
Company facts updated Sep 9, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI20M0.00%2.3T USD0.03%$376-0.42%
iShares Russell 2000 ETFIWM18.5M0.02%80.51B USD0.19%$290.75-1.33%
Vanguard Morningstar Small-Cap ETFVB14.44M0.01%183.4B USD0.03%$294.39-1.13%
Vanguard Morningstar Small-Cap Growth ETFVBK8.29M0.02%43.8B USD0.05%$343.4-1.29%
Vanguard Extended Market ETFVXF8.08M0.01%93.7B USD0.05%$238.92-1.01%
iShares Russell 2000 Growth ETFIWO4.56M0.03%14.7B USD0.24%$371.33-1.53%
Vanguard Russell 2000 ETFVTWO4.39M0.02%17.4B USD0.06%$117.56-1.33%
Schwab U.S. Small-Cap ETFSCHA3.2M0.01%22.86B USD0.03%$34.125-0.97%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
